title: The CROES percutaneous nephrolithotomy global study: the influence of body mass index on outcome.
abstract: OBJECTIVE
  In addition to more commonly forming stones, obese patients present a number of challenges when undergoing percutaneous nephrolithotomy. We evaluated percutaneous nephrolithotomy outcomes in 3,709 patients stratified by body mass index.
  
  
  METHODS
  A prospective database administered by CROES (Clinical Research Office of the Endourological Society) captured data on 5,803 patients treated with percutaneous nephrolithotomy between November 2007 and December 2009. Patients with known solitary kidney, previous percutaneous nephrolithotomy and congenital abnormalities were excluded from analysis. For statistical analysis patients were categorized as normal weight--body mass index 18.5 to 25 kg/m(2), overweight--25 to 30, obese--30 to 40 and super obese--greater than 40.
  
  
  RESULTS
  During the study period 5,803 patients underwent percutaneous nephrolithotomy, of whom 3,709 met the inclusion criteria. As expected, obesity was associated with significantly higher rates of comorbid conditions and anticoagulant use (p < 0.001). Operative time was significantly longer in obese patients and use of a balloon device for tract dilation was more common (each p < 0.001). The stone-free rate decreased with obesity (p = 0.009), corresponding to a significantly higher re-treatment rate in this group (p < 0.001). No difference was seen in length of stay or the transfusion rate. No significant difference was seen in the overall complication rate among the 4 groups (p = 0.707).
  
  
  CONCLUSIONS
  Percutaneous nephrolithotomy may be done safely in obese patients, although with a longer operative time, an inferior stone-free rate and a higher re-intervention rate.
authors.affiliation: Division of Urology, Department of Surgery, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada.
authors.forename: Andrew
authors.initials: A
authors.lastname: Fuller
authors.forename: Hassan
authors.initials: H
authors.lastname: Razvi
authors.forename: John D
authors.initials: JD
authors.lastname: Denstedt
authors.forename: Linda
authors.initials: L
authors.lastname: Nott
authors.forename: Margaret
authors.initials: M
authors.lastname: Pearle
authors.forename: Furio
authors.initials: F
authors.lastname: Cauda
authors.forename: Damien
authors.initials: D
authors.lastname: Bolton
authors.forename: Antonio
authors.initials: A
authors.lastname: Celia
authors.forename: Jean
authors.initials: J
authors.lastname: de la Rosette
mesh_terms: D015992:Body Mass Index; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007669:Kidney Calculi / Q000150:complications / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009403:Nephrostomy, Percutaneous / Q000379:methods*; D009765:Obesity / Q000150:complications*; D011446:Prospective Studies; D016896:Treatment Outcome